nyuuzyou/wikis huggingface dataset:
Brexucabtagene autoleucel (Tecartus)

==Mechanism of action==
From the NCI Drug Dictionary: A preparation of autologous peripheral blood T lymphocytes (PBTL) that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of brexucabtagene autoleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell-specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development. Brexucabtagene autoleucel has the same construct as axicabtagene ciloleucel, but differs in the manufacturing process in that brexucabtagene autoleucel includes specific T-cell selection and lymphocyte enrichment necessary for activity against certain B-cell malignancies.
==Toxicity management==
*Link to REMS 
==Diseases for which it is established (work in progress)==
*B-cell acute lymphoblastic leukemia
==Diseases for which it is used==
*Mantle cell lymphoma
==History of changes in FDA indication==
*2020-07-24: Granted accelerated approval for the treatment of adult patients with relapsed/refractory mantle cell lymphoma. (Based on ZUMA-2)
*2021-10-01: Approved for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). (Based on ZUMA-3)
==History of changes in EMA indication==
*2020-12-14: Initial conditional authorization.
== Patient Drug Information==
*Brexucabtagene autoleucel (Tecartus) Package InsertBrexucabtagene autoleucel (Tecartus) Package Insert
==Also known as==
*Code name: KTE-X19
*Generic name: brexu-cel
*Brand name: Tecartus
==References==
Category:Anti-CD19 CAR T-cells
Category:Anti-CD3 cellular therapy
Category:Anti-CD19 cellular therapy
Category:Anti-CD28 cellular therapy
Category:Intravenous medications
Category:B-cell acute lymphoblastic leukemia medications
Category:Mantle cell lymphoma medications
Category:FDA approved in 2020
Category:EMA approved in 2020
Category:REMS program
Category:Kite Pharma product
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The Dana-Farber/Partners CancerCare training program in hematology/oncology prepares academically oriented physicians to become leaders in clinical and laboratory investigation and clinical teaching."
==Basic information==
Name: Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute Hematology Oncology Fellowship or Dana-Farber/Partners CancerCare Hematology/Oncology Fellowship Program
Fellowship program website: https://www.dana-farber.org/Education-and-Training/Fellowships-and-Training-Programs/HematologyOncology-Fellowships.aspx
ACGME ID: 1552421073
===Leadership===
*Program Director: 
===Fellowship Coordinator===
Kim Bremner
Phone: 617-632-3474
Fax: 617-632-2260
Email: kim_bremner@dfci.harvard.edu
==Application process and requirements==
https://www.dana-farber.org/Education-and-Training/Fellowships-and-Training-Programs/HematologyOncology-Fellowships.aspx
===Process===
*Applications accepted starting on: 
*Application deadline: August 31
*Applications submitted through ERAS
===Requirements===
==Statistics==
*Number of fellowship positions available per year: 
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
"The program involves an initial year of intensive clinical training, followed by two or more years of in-depth clinical and/or basic research training. There is also the opportunity for an additional six months of clinical experience."
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*Dana-Farber Cancer Institute
*Brigham and Women's Hospital
*Massachusetts General Hospital
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Buserelin (Suprefact)

==Mechanism of action==
Gonadotropin-releasing hormone (GnRH) analog, inhibits pituitary gonadotropin secretion, which suppresses ovarian and testicular steroidogenesis.
==Diseases for which it is used==
*Prostate cancer
==History of changes in EMA indication==
*1984-08-16: EURD
==Also known as==
*Code names: HOE-766, ICI-123215, S74-6766
*Brand names: Bigonist, Etilamide, Profact, Receptal, Suprecur, Suprefact
Category:Drugs
Category:Subcutaneous medications
Category:Nasal medications
Category:GnRH analogs
Category:Prostate cancer medications
Category:EMA approved in 1984
Category:Stub
Busulfan (Myleran)

==General information==
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.Busulfan (Myleran) package insert Busulfan (Myleran) package insert (locally hosted backup)Busulfan (Busulfex) package insert Busulfan (Busulfex) package insert (locally hosted backup)
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape,or the prescribing information.
==Diseases for which it is used==
*Acute myeloid leukemia
*Acute promyelocytic leukemia
*Chronic lymphocytic leukemia
*Chronic myeloid leukemia
*Ewing sarcoma
*Non-Hodgkin lymphoma
**Anaplastic large cell lymphoma
**CNS lymphoma
**Diffuse large B-cell lymphoma
**Mantle cell lymphoma
**NK- and T-cell lymphoma
**Peripheral T-cell lymphoma
**Primary mediastinal B-cell lymphoma
*Myelodysplastic syndrome
*Neuroblastoma
==Diseases for which it was used==
*Multiple myeloma
==Patient drug information==
*Busulfan (Myleran) package insert
*Busulfan (Myleran) patient drug information (Chemocare)Busulfan (Myleran) patient drug information (Chemocare)
*Busulfan (Myleran) patient drug information (UpToDate)Busulfan (Myleran) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1954-06-26: Initial FDA approval
*2003-01-23 (oldest label available at Drugs @ FDA): indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. (No supporting studies are cited)
==History of changes in EMA indication==
*2003-07-09: EURD
==History of changes in PMDA indication==
*2020-03-25: New indication and a new dosage for the conditioning treatment of malignant lymphoma in patients prior to autologous hematopoietic stem-cell transplantation.
==Also known as==
*Brand names: Busilvex, Busulfex, Myleran
==References==
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Alkyl sulfonates
Category:Irritant
Category:Acute myeloid leukemia medications
Category:Acute promyelocytic leukemia medications
Category:Anaplastic large cell lymphoma medications
Category:Chronic lymphocytic leukemia medications
Category:Chronic myeloid leukemia medications
Category:CNS lymphoma medications
Category:Diffuse large B-cell lymphoma medications
Category:Ewing sarcoma medications
Category:Mantle cell lymphoma medications
Category:Myelodysplastic syndrome medications
Category:Neuroblastoma medications
Category:NK- and T-cell lymphoma medications
Category:Peripheral T-cell lymphoma medications
Category:Primary mediastinal B-cell lymphoma medications
Category:Multiple myeloma medications (historic)
Category:FDA approved in 1954
Category:EMA approved in 2003
CART-EGFRvIII

==Mechanism of action==
T cells redirected to the epidermal growth factor receptor variant III (EGFRvIII) mutation by a chimeric antigen receptor (CAR)
Category:Anti-EGFRvIII CAR T-cells
Category:Intravenous medications
Category:Glioblastoma medications (investigational)
Category:Investigational drugs
Category:Stub
CAR T-cell toxicity management

This page is in process of being created. For preparatory regimens for CAR T-cell therapy, please go to this page.
==Grading toxicity==
===CTCAE===
*Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) - Adverse event grading for clinical trialsCommon Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) - Adverse event grading for clinical trials
:*CTCAE 5x7" small booklet format local backupCTCAE 5x7" small booklet format local backup
:*CTCAE 8.5x11" letter size format local backupCTCAE 8.5x11" letter size format local backup
==Evaluation==
==Management==
==References==
Category:Supportive oncology
CARv3-TEAM-E T-cells

==Mechanism of action==
anti-EGFR variant III CAR T-cells
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Glioblastoma===
#INCIPIENT: Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, Maus MV. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med. 2024 Apr 11;390(14):1290-1298. Epub 2024 Mar 13. link to original article link to PMC article EuroPMC NCT05660369
Category:Intravenous medications
Category:Anti-EGFRvIII CAR T-cells
Category:Glioblastoma medications (investigational)
Category:Investigational drugs
CD68-ET3-LV

Gene therapy
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Hemophilia A===
#Srivastava A, Abraham A, Aboobacker F, et al. Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A. The New England Journal of Medicine. 2024 Dec;392:450-457. link to original article EuroPMC NCT05265767
==Also known as==
*Code name: CD68-ET3-LV
Category:Drugs
Category:Intravenous medications
Category:Inherited coagulopathy medications (investigational)
Category:Investigational drugs
Category:Stub
CNS carcinoma

Back to Top
This page has regimens and guidelines that are not specific to any one type of cancer. For disease-specific regimens and guidelines, please go to the following pages:
*Breast cancer, CNS metastases
*Non-small cell lung cancer, CNS metastases
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==ASCO==
*2022: Schiff et al. Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline EuroPMC
==ASCO/SNO/ASTRO==
*2021: Vogelbaum et al. Treatment for Brain Metastases EuroPMC
==EANO/ESMO==
*2023: Le Rhun et al. Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up EuroPMC
**2017: Le Rhun et al. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours EuroPMC
*2021: Le Rhun et al. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours EuroPMC
==ISRS==
*2022: Grishcuk et al. ISRS Technical Guidelines for Stereotactic Radiosurgery: Treatment of Small Brain Metastases (≤1 cm in Diameter) EuroPMC
*2018: Chao et al. Stereotactic Radiosurgery in the Management of Limited (1-4) Brain Metasteses: Systematic Review and International Stereotactic Radiosurgery Society Practice Guideline EuroPMC
==NCCN==
*NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Central Nervous System Cancers.
=All lines of therapy=
==Whole brain irradiation==
WBRT: Whole-Brain Radiation Therapy
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Knisely et al. 2007 (RTOG 0118)	2002-2004 	Phase 3 (C)	Thalidomide & WBRT	Did not meet primary endpoint of OS
====Radiotherapy====
*Whole-brain irradiation 250 cGy fractions x 15 (total dose: 3750 cGy)
One course
===References===
#RTOG 0118: Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):79-86. Epub 2007 Dec 31. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00033254
Category:CNS carcinoma regimens
Category:Disease-specific pages
Category:CNS cancers
CNS lymphoma - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main CNS lymphoma page for regimens that include active anticancer treatment.
=Consolidation after upfront therapy=
==Observation==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Thiel et al. 2010 (G-PCNSL-SG-1)	2000-2009 	Phase 3 (E-de-esc)	Whole-brain irradiation	Inconclusive whether non-inferior OS (primary endpoint)Median OS: 37.1 vs 32.4 mo(HR 0.94, 95% CI 0.71-1.25)
No further treatment.
====Preceding treatment====
*G-PCNSL-SG-1, before 2006: Induction High-dose methotrexate x 6
*G-PCNSL-SG-1, after 2006: Induction High-dose methotrexate & ifosfamide x 6
===References===
# G-PCNSL-SG-1: Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010 Nov;11(11):1036-47. Epub 2010 Oct 20. link to original article EuroPMC NCT00153530
## Update: Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology. 2015 Mar 24;84(12):1242-8. Epub 2015 Feb 25. link to original article EuroPMC
Category:CNS lymphoma regimens
Category:Disease-specific pages
Category:CNS cancers
Category:Null regimens
Cabazitaxel (Jevtana)

==General information==
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization, inhibiting interphase/mitosis processes.Cabazitaxel (Jevtana) package insert Cabazitaxel (Jevtana) package insert (locally hosted backup)Jevtana manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*Prostate cancer
==Patient drug information==
*Cabazitaxel (Jevtana) package insert
*Cabazitaxel (Jevtana) patient drug information (Chemocare)Cabazitaxel (Jevtana) patient drug information (Chemocare)
*Cabazitaxel (Jevtana) patient drug information (UpToDate)Cabazitaxel (Jevtana) patient drug information (UpToDate)
==History of changes in FDA indication==
*2010-06-17: Initial approval in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. (Based on TROPIC)
*2017-09-14: Approved at a lower dose (20 mg/m2 every 3 weeks) in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. (Based on PROSELICA)
*2020-12-18: Approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. (Based on CARD)
==History of changes in EMA indication==
*2011-03-17: Initial marketing authorization as Jevtana. Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. (Based on TROPIC)
==History of changes in Health Canada indication==
*2011-06-06: Initial notice of compliance for the treatment of patients with castration resistant (hormone refractory) metastatic prostate cancer previously treated with a docetaxel containing regimen.
==History of changes in PMDA indication==
*2014-07-04: Initial approval for the treatment of prostate cancer.
==Also known as==
*Code names: XRP-6258, TXD-258, RPR-116258A
*Brand names: Cabapan, Cabaxan, Cabazither, Cabtana, Cazat, Jevatax, Jevtana, Kabanat, Procabazi, Qtervaxia, Z-Texel
==References==
Category:Drugs
Category:Intravenous medications
Category:Taxanes
Category:Prostate cancer medications
Category:EMA approved in 2011
Category:FDA approved in 2010
Category:Health Canada approved in 2011
Category:PMDA approved in 2014
Cadonilimab (AK-104)

==Mechanism of action==
From the NCI Drug Dictionary: A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cadonilimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with cadonilimab may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.
==Diseases for which it is used==
*Cervical cancer
*Gastric cancer
==History of changes in NMPA indication==
*2022-06-29: Initial approval for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy. (Based on COMPASSION-13)
*2024-09-30: Approved in combination with fluoropyrimidine and platinum-based chemotherapy for first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. (Based on COMPASSION-15)
==Also known as==
*Code name: AK-104
Category:Drugs
Category:Intravenous medications
Category:Anti-CTLA-4-PD-1 bispecific antibodies
Category:Cervical cancer medications
Category:Gastric cancer medications
Category:NMPA approved in 2022
Calaspargase (Asparlas)

==General information==
Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase. This product provides for a longer interval between doses compared to other available pegaspargase products.
Route: IV, IM
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*B-cell acute lymphoblastic leukemia
*T-cell acute lymphoblastic leukemia
==History of changes in FDA indication==
*2018-12-20: Initial approval as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years. (Based on COG AALL07P4)
== Patient Drug Information==
*Calaspargase (Asparlas) Package InsertCalaspargase (Asparlas) Package Insert
==Also known as==
*Generic name: calaspargase pegol-mknl
*Brand name: Asparlas
==References==
Category:Drugs
Category:Pegylated medications
Category:Intramuscular medications
Category:Intravenous medications
Category:Neutral
Category:Asparagine-specific enzymes
Category:B-cell acute lymphoblastic leukemia medications
Category:T-cell acute lymphoblastic leukemia medications
Category:FDA approved in 2018
Calcium phosphate rinse (Caphosol)

==General information==
Class/mechanism: Electrolyte solution designed to mimic the ionic and pH balance of human saliva. The solution is used to help maintain moisture in mucosa of the mouth, tongue, and throat in patients experiencing xerostomia/hyposalivation or mucositis.Calcium phosphate rinse (Caphosol) package insert Calcium phosphate rinse (Caphosol) package insert (locally hosted backup)Caphosol manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Conditions for which it is used==
*Xerostomia/hyposalivation 
*Mucositis
==Patient drug information==
*Calcium phosphate rinse (Caphosol) package insert
*Artificial saliva patient drug information (UpToDate)Artificial saliva patient drug information (UpToDate)
==Also known as==
*Generic names: artificial saliva, supersaturated calcium phosphate rinse
*Brand name: Caphosol
*Brand name solutions with similar uses include: Aquoral, Biotene Moisturizing Mouth Spray, Biotene Oral Balance, Entertainer's Secret, Moi-Stir, Mouth Kote, Numoisyn, Oasis, and SalivaSure.
==References==
Category:Drugs
Category:Oral medications
Category:Mucositis prevention